London-based Ternary Therapeutics is betting that AI-engineered “molecular glues” can tame chronic inflammation, opening new doors to longevity medicine.
located in London Triple therapy Raised $4.4 million (€4.1 million) in a seed round led by Paris-based VC daphni, alongside Pace Ventures, i&i Biotech Fund and Future Planet Capital. On paper, a $4.4 million seed may seem modest, but in today’s biotech climate, it’s more like a sign of selective confidence. Investors are ready to back a company that promises to solve one of the most difficult problems in drug discovery.
Ternary is attempting targeted protein degradation, an area that has generated excitement but also frustration. Instead of standard “lock and key” drugs that block proteins, Ternary develops molecular glues (1). These are small molecules that can bring two proteins together, introduce a harmful protein into a natural cellular system, or modulate biology in ways that conventional drugs often cannot.
It’s like a match for proteins. Instead of dealing with the problem, you let the system fix it on its own. This is a subtle but powerful approach, especially for proteins involved in persistent inflammatory diseases.
Ternary’s primary focus is inflammation and neuroinflammation—areas that resonate far beyond classical immune diseases. Chronic low-grade inflammation, sometimes referred to as “inflammation,” is now understood as one of the key processes leading to age-related decline, from neurodegeneration to metabolic disorders. Coping with it effectively can be a gateway to healthy aging.
Tools that can pinpoint these proteins could change our view of age-related diseases. Ternary is still in the preclinical stage, but the implications for longevity medicine are hard to ignore. Better control of inflammation may help people with a lower chronic disease burden.
Historically, molecular glues were discovered mostly by accident. By chance, a promising compound was found in the lab, and researchers reverse-engineered to understand why it worked. This makes the field fun but unpredictable. Ternary aims to change that.
Its platform uses AI combined with physics-informed modeling and “closed-loop” laboratory testing. In practical terms, AI suggests potential glue molecules, the lab tests them, and the results feed back into the system for the next round of refinement. The goal: a repeatable engine for drug design, not relying on luck.
Biotech investment has changed. Investors now favor companies that show solid, defensible science rather than flashy AI slides. Ternary’s lineup ticks both boxes—a clear AI approach that’s directly tied to material biology, rather than an abstract algorithm that chases down every possible drug target.
The appointment of Ian Taylor to the Ternary Board reinforces the story. Taylor, the former president of R&D at Arvinas in the US, brings confidence to the protein degradation space – an area plagued by both clinical and commercial setbacks. His presence suggests Ternari is serious about turning the platform’s science into drugs that can reach the clinic.
Even with strong support, time seems to be running out. California based f5 Therapeutics recently closed after six years, citing a tough funding environment for early-stage biotechs. Ternary’s success in securing investors, however, reflects a growing confidence in European technologies, especially companies that address the challenge of “hard mode” rather than superficial implementation of AI.
Chronic inflammation is a cornerstone of the biology of aging. The idea that AI-designed molecules can selectively alter proteins associated with inflammation is more than just a lab experiment—it’s a potential tool for a healthier, longer life.
Of course, the road from seed funding to actual treatments is long. Preclinical data should be used to inform partnerships, then clinical candidates, and ultimately treatments that demonstrate safety and efficacy in humans. But Ternary’s story is already noteworthy: it is indicative of a mature biotech ecosystem in Europe that is willing to bet on science-based platforms that have long-term relevance.
For our readers, the bottom line is this: the fight against age-related diseases is increasingly becoming a computational and biological puzzle. Companies like Ternary are building engines that could one day translate complex biology into actionable interventions — and perhaps, in time, allow us to age more gracefully.
